Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN006 Bivalent mRNA RSV Vaccine in Healthy Adults
NCT06287450Phase 1Not yet recruiting
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Apr 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Phase 1, randomised, double-blind trial of IN006 in respiratory syncytial virus infection (RSV) (7 cohorts), sponsored by Shenzhen Shenxin Biotechnology Co., Ltd. Primary endpoints: Percentage of Participants With Solicited Local and Systemic Adverse Reactions at 14 days, Percentage of Participants With Unsolicited Adverse Events at 28 days and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
IN006
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06287450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287450.